Patient Support

JANSSEN CAREPATH PROVIDES ACCESS, AFFORDABILITY, AND TREATMENT SUPPORT TO HELP YOUR PATIENTS START ON TREMFYA^®

Access support

to help navigate payer processes

Janssen CarePath helps verify insurance coverage for your patients and provides reimbursement information.

Janssen CarePath provides:

Benefits investigation support
Prior authorization support and status monitoring
Information on exceptions and appeals process
Coding and billing information, if needed

Submit a Prescription Enrollment Form to get your patient started

Visit Janssen CarePath

Affordability support

to help your patients start and stay on treatment you prescribe

Janssen CarePath can help you find out what affordability assistance may be available for your patients taking TREMFYA®

Janssen CarePath Savings Program

Eligible patients using commercial insurance pay $5 for each injection*

Enroll and Activate

*Up to $20,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for TREMFYA® medication. See full eligibility requirements.

Treatment support

to help your patients get informed and stay on prescribed treatment

Janssen CarePath provides additional support to your patients, including Care Coordination, Janssen Nurse Support,^† treatment reminders, and patient education.

PsO Simple Trial Program

Helps patients start on TREMFYA® to evaluate safety and efficacy. At the conclusion of the PsO Simple Trial Program, HCPs and their patients can decide if it is clinically appropriate to continue treatment with TREMFYA®.

Call Janssen CarePath for eligibility and program details.

Enrollment Form

^†The nurse program is limited to education for patients about their Janssen therapy, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, or provide case management services.

Call 877-CarePath (877-227-3728)

Monday to Friday, 8:00 AM to 8:00 PM ET

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA^®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v1